Australija - engleski - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ciprofloxacin hydrochloride, quantity: 277.5 mg (equivalent: ciprofloxacin, qty 250 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; maize starch; crospovidone; pregelatinised maize starch; titanium dioxide; hypromellose; macrogol 8000; triacetin; polydextrose - for the treatment of infections caused by susceptible organisms in the following conditions: - urinary tract infections - gonorrhoeal urethritis and cervicitis - gastroenteritis - bronchial infections - skin and skin structure infections - bone and joint infections - chronic bacterial prostatitis of mild to moderate severity.- inhalational anthrax (post-exposure). to reduce the incidence or progression of disease following exposure to aerosolised bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note:1. typhoid and paratyphoid infections and infections due to multi-resistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in case with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. c-flox is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered. consideration should be given to available official guidance on the appropriate use of antibacterial agents.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ciprofloxacin hydrochloride, quantity: 291.11 mg (equivalent: ciprofloxacin, qty 250 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; pregelatinised maize starch; maize starch; crospovidone; colloidal anhydrous silica; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3000 - ciprol is indicated for the treatment of infections caused by susceptible organisms in the conditions listed: urinary tract infections, gonorrhoeal urethritis and cervicitis, gastroenteritis, bronchial infections, skin and skin structure infections, bone and joint infections, chronic bacterial prostatitis of mild to moderate severity. note: 1. typhoid and paratyphoid infections and infections due to multiresistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying agents, additional therapy should be considered.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ciprofloxacin hydrochloride, quantity: 582.21 mg (equivalent: ciprofloxacin, qty 500 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; maize starch; magnesium stearate; crospovidone; pregelatinised maize starch; colloidal anhydrous silica; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3000 - ciprol is indicated for the treatment of infections caused by susceptible organisms in the conditions listed: urinary tract infections, gonorrhoeal urethritis and cervicitis, gastroenteritis, bronchial infections, skin and skin structure infections, bone and joint infections, chronic bacterial prostatitis of mild to moderate severity. note: 1. typhoid and paratyphoid infections and infections due to multiresistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying agents, additional therapy should be considered.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ciprofloxacin hydrochloride, quantity: 873.32 mg (equivalent: ciprofloxacin, qty 750 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; pregelatinised maize starch; crospovidone; maize starch; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3000 - ciprol is indicated for the treatment of infections caused by susceptible organisms in the conditions listed: urinary tract infections, gonorrhoeal urethritis and cervicitis, gastroenteritis, bronchial infections, skin and skin structure infections, bone and joint infections, chronic bacterial prostatitis of mild to moderate severity. note: 1. typhoid and paratyphoid infections and infections due to multiresistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be preformed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated beforeresults of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-postitive aerobic bacteria. if anaerobic organisms are suspected as accompanying agents, additional therapy should be considered.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ciprofloxacin hydrochloride, quantity: 873 mg (equivalent: ciprofloxacin, qty 750 mg) - tablet, film coated - excipient ingredients: hypromellose; titanium dioxide; croscarmellose sodium; colloidal anhydrous silica; povidone; sodium starch glycollate type a; stearic acid; macrogol 6000; microcrystalline cellulose; purified talc; magnesium stearate - ciprofloxacin sandoz is indicated for the treatment of infections caused by susceptible organisms in the following conditions: urinary tract infections, gonorrhoeal urethritis and cervicitis, gastroenteritis, bronchial infections, skin and skin structure infections, bone and joint infections, chronic bacterial prostatitis of mild to moderate severity. typhoid and paratyphoid infections and infections due to multiresistant staph. aureus are excluded from the above due to insufficient data. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the medicine of choice in cases with gram-positive infections, such as pneumonia due to strep. pneumoniae. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of n. gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin sandoz may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin sandoz is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents additional therapy should be considered.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ciprofloxacin hydrochloride, quantity: 582 mg (equivalent: ciprofloxacin, qty 500 mg) - tablet, film coated - excipient ingredients: stearic acid; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type a; croscarmellose sodium; povidone; hypromellose; macrogol 6000; purified talc; titanium dioxide; magnesium stearate - ciprofloxacin sandoz is indicated for the treatment of infections caused by susceptible organisms in the following conditions: urinary tract infections, gonorrhoeal urethritis and cervicitis, gastroenteritis, bronchial infections, skin and skin structure infections, bone and joint infections, chronic bacterial prostatitis of mild to moderate severity. typhoid and paratyphoid injections and injections due to multiresistant staph. aureus are excluded from the above due to insufficient data. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the medicine of choice in cases with gram-positive infections, such as pneumonia due to strep. pneumoniae. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of n. gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin sandoz may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin sandoz is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents additional therapy should be considered.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ciprofloxacin hydrochloride, quantity: 291 mg (equivalent: ciprofloxacin, qty 250 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate type a; microcrystalline cellulose; stearic acid; purified talc; colloidal anhydrous silica; croscarmellose sodium; povidone; hypromellose; magnesium stearate; titanium dioxide; macrogol 6000 - ciprofloxacin sandoz is indicated for the treatment of infections caused by susceptible organisms in the following conditions: urinary tract infections, gonorrhoeal urethritis and cervicitis, gastroenteritis, bronchial infections, skin and skin structure infections, bone and joint infections, chronic bacterial prostatitis of mild to moderate severity. typhoid and paratyphoid infections and infections due to multiresistant staph. aureus are excluded from the above due to insufficient data. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the medicine of choice in cases with gram-positive infections, such as pneumonia due to strep. pneumoniae. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of n. gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin sandoz may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin sandoz is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ciprofloxacin hydrochloride, quantity: 583 mg (equivalent: ciprofloxacin, qty 500 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; maize starch; crospovidone; colloidal anhydrous silica; magnesium stearate; hypromellose; macrogol 4000; titanium dioxide - ciprofloxacin is indicated for the treatment of infections caused by susceptible organisms in the following conditions listed below: urinary tract infections; gonorrhoeal urethritis and cervicitis; gastroenteritis; bronchial infections; skin and skin structure infections; bone and joint infections; chronic bacterial prostatitis of mild to moderate severity. inhalational anthrax (post exposure): to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note: typhoid and paratyphoid infections and infections due to multi-resistant staphylococcus aureus are excluded from the above due to insufficient data. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pne

Australija - engleski - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - ciprofloxacin hydrochloride, quantity: 832.5 mg (equivalent: ciprofloxacin, qty 750 mg) - tablet, film coated - excipient ingredients: magnesium stearate; maize starch; sodium starch glycollate type a; microcrystalline cellulose; purified talc; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 400 - the treatment of infections caused by susceptible organisms in the conditions listed below: - urinary tract infections - gonorrhoeal urethritis and cervicitis - gastroenteritis, - bronchial infections - skin and skin structure infections - bone and joint infections - chronic bacterial prostatitis of mild to moderate severity. note: 1. typhoid and paratyphoid infections and infections due to multiresistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in case with gram- positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - ciprofloxacin hydrochloride, quantity: 555 mg (equivalent: ciprofloxacin, qty 500 mg) - tablet, film coated - excipient ingredients: magnesium stearate; sodium starch glycollate type a; maize starch; purified talc; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 400 - the treatment of infections caused by susceptible organisms in the conditions listed below: - urinary tract infections - gonorrhoeal urethritis and cervicitis - gastroenteritis, - bronchial infections - skin and skin structure infections - bone and joint infections - chronic bacterial prostatitis of mild to moderate severity. note: 1. typhoid and paratyphoid infections and infections due to multiresistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in case with gram- positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered.